We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+29.87%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$799M
AUM Growth
+$123M
Cap. Flow
+$31.7M
Cap. Flow %
3.97%
Top 10 Hldgs %
87.4%
Holding
24
New
–
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$43.2M
2
CABA icon
Cabaletta Bio
CABA
+$10.8M
3
UPB
Upstream Bio Inc
UPB
+$1.33M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$18.8M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$3.89M
3
NAUT icon
Nautilus Biotechnolgy
NAUT
+$923K

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.34B
$194M 24.29%
10,719,110
– –
CDTX
2
DELISTED
Cidara Therapeutics
CDTX
$122M 15.24%
2,500,680
+1,797,600
+256% +$43.2M
NUVL
3
DELISTED
Nuvalent
NUVL
$110M 13.82%
1,447,267
– –
PHVS icon
4
Pharvaris
PHVS
$2.44B
$58.1M 7.27%
3,303,381
– –
DNTH icon
5
Dianthus Therapeutics
DNTH
$6.09B
$46.2M 5.79%
2,482,250
-207,457
-8% -$3.89M
SVRA icon
6
Savara
SVRA
$1.19B
$40.1M 5.02%
17,600,621
– –
SLDB icon
7
Solid Biosciences
SLDB
$900M
$38.5M 4.82%
7,911,669
– –
IRON icon
8
Disc Medicine
IRON
$2.97B
$30.9M 3.87%
583,500
-400,000
-41% -$18.8M
OLMA icon
9
Olema Pharmaceuticals
OLMA
$1.05B
$29.2M 3.65%
6,843,954
– –
RPID icon
10
Rapid Micro Biosystems
RPID
$86.2M
$29.1M 3.64%
8,434,560
– –
UPB
11
Upstream Bio Inc
UPB
$395M
$26.8M 3.35%
2,439,538
+144,216
+6% +$1.33M
CABA icon
12
Cabaletta Bio
CABA
$455M
$14.7M 1.84%
9,677,125
+6,916,237
+251% +$10.8M
TNGX icon
13
Tango Therapeutics
TNGX
$4.41B
$13.9M 1.74%
2,712,008
– –
ANNX icon
14
Annexon
ANNX
$886M
$12.6M 1.58%
5,249,069
– –
KYTX icon
15
Kyverna Therapeutics
KYTX
$484M
$10.3M 1.29%
3,368,370
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$420M
$8.95M 1.12%
2,485,638
– –
XLO icon
17
Xilio Therapeutics
XLO
$60.3M
$3.1M 0.39%
326,201
– –
IPSC icon
18
Century Therapeutics
IPSC
$361M
$3.02M 0.38%
5,410,361
– –
MRSN
19
DELISTED
Mersana Therapeutics
MRSN
$2.56M 0.32%
346,547
– –
CCCC icon
20
C4 Therapeutics
CCCC
$412M
$1.59M 0.2%
1,111,910
– –
IVVD icon
21
Invivyd
IVVD
$218M
$1.29M 0.16%
1,799,595
– –
XFOR icon
22
X4 Pharmaceuticals
XFOR
$460M
$1.07M 0.13%
563,859
– –
NAMSW icon
23
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$800K 0.1%
100,000
– –
NAUT icon
24
Nautilus Biotechnolgy
NAUT
$115M
– –
-1,072,421
Closed -$923K

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2025 Portfolio in Review

As of Q2 2025, Bain Capital Life Sciences Investors held 24 positions worth $799M, up 18% from $676M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Bain Capital Life Sciences Investors deployed $31.7M of net new capital in Q2 2025, adding to 3 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Disc Medicine, an estimated $18.8M trimmed.

  • Bain Capital Life Sciences Investors added most to Cidara Therapeutics in Q2 2025, an estimated $43.2M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2025 reduction was Disc Medicine, cutting an estimated $18.8M.
  • Bain Capital Life Sciences Investors fully exited Nautilus Biotechnolgy in Q2 2025, selling an estimated $923K.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 87% of its $799M portfolio in Q2 2025.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 1 in Q2 2025.
  • Bain Capital Life Sciences Investors's portfolio value rose 18% quarter-over-quarter to $799M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2025, filed 14 Aug 2025.